• Home
  • Search Results

Search Results

2518 studies match your search

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

The purpose of this study is to determine if MIRV plus Bev can help to prevent your cancer from returning or delaying your cancer's return.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Other Cancers, Ovarian)
Open

Dupilumab for Eosinophilic Esophagitis with Severe Strictures (DESTRICT Study)

Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.

Age & Gender
  • 16 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Stomach, Digestion and Gut Health
  • Ear, Nose, and Throat
Open

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma

Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety of giving a new drug to patients with multiple myeloma.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Open

Study of sacituzumab govitecan with or without pembrolizumab in Metastatic TNBC

Have you been diagnosed with triple negative breast cancer? If so, you may be able to take part in a research study looking at the safety of giving a new drug called Sacituzumab Govitecan with or without a drug called Pembrolizumab to patients with PDL-1-negative metastatic triple negative breast cancer.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Breast)

Radiation, PARP inhibition, and immunotherapy for breast cancer brain metastasis

The purpose of this research study is to see if adding the PARP inhibitor olaparib concurrently with SRS followed by immunotherapy (durvalumab) and chemotherapy will lead to better control of breast cancer that has spread to the brain better than the standard approach.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Brain, Head, Nervous System
  • Cancer (Brain and Other Nervous System, Breast)
Not currently enrolling

Physical Activity in College-Age Native American Adults

The purpose of this study is to assess the physical activity practices of college-age Native American adults.

Age & Gender
  • 18 years ~ 25 years
  • Male, Female, Gender Inclusive
Study Interest
  • Healthy Volunteer or General Population
  • Minority Health
Visit Location
100% Remote (online, phone, text)
Open

LCCC 1855/MASCOT: Manufacturing and Analysis of Stem Cells from Skin Cells for Ovarian Cancer Treatment

Are you suspected of having or have been diagnosed with ovarian cancer? if so, you may be able to participate in a research study looking at creating personalized stem cells from the skin of ovarian cancer patients to see if these stem cells can attack cancer cells. This work may be able to help us find more treatment options for ovarian cancer patients in the future.

Age & Gender
  • 18 years ~ 99 years
  • Female
Study Interest
  • Cancer (Ovarian)
Open

SAMURAI Study- Stereotactic radiation therapy with immune therapy for patients with Renal Cell Cancer

Do you have renal cell cancer that has spread beyond your kidney and surgery is not recommended? You may be able to take part in a research study to help us learn if adding radiation therapy to your usual cancer treatment may help your cancer shrink.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Kidney)

NBTXR3 With or Without Cetuximab in locally advanced head & neck squamous cell carcinoma

The purpose of this study is to find out if an investigational medication (NBTXR3) could help elderly patients with locally advanced head & neck squamous cell carcinoma who are otherwise ineligible to receive platinum-based chemotherapy. This study will help to determine the recommended dose/s of NBTXR3. The study medication is injected directly into the tumor and is activated by radiation therapy in combination with anti-PD1 therapy.

Age & Gender
  • 65 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck, Liver, Lung, and 2 more)
Open

Phase 2 study of isatuximab plus lenalidomide and dexamethasone in highly toxicity-vulnerable subjects with newly diagnosed multiple myeloma

Do you have newly-diagnosed multiple myeloma? If so, you may be able to participate in a research study looking at the safety, efficacy, and tolerability of giving isatuximab in combination with lenalidomide and dexamethasone at lower doses.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research